ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
세팔로스포린 약물 시장 규모는 최근 꾸준히 확대하고 있습니다. 2025년 171억 7,000만 달러에서 2026년에는 178억 8,000만 달러로, CAGR 4.1%로 성장할 것으로 예상됩니다. 지난 몇 년간의 성장은 세균 감염의 높은 유병률, 세팔로스포린의 임상적 유효성 입증, 의사들의 광범위한 인식, 다세대 약품의 가용성, 병원에서의 항생제 사용 확대 등에 기인하는 것으로 보입니다.
세팔로스포린 약물 시장 규모는 향후 몇 년간 꾸준한 성장이 전망됩니다. 2030년에는 210억 2,000만 달러에 달하고, CAGR은 4.1%가 될 전망입니다. 예측 기간의 성장 요인으로는 항균제 내성 우려 증가, 차세대 항생제 수요, 병원 인프라 확충, 수술 건수 증가, 신흥 헬스케어 시장에서의 지속적인 수요 등을 꼽을 수 있습니다. 예측 기간 동안 주요 동향으로는 광범위 항생제에 대한 지속적인 수요, 다양한 감염 유형에 대한 광범위한 사용, 고세대 세팔로스포린의 사용 증가, 제네릭 의약품의 강력한 존재감, 주사제 세팔로스포린의 병원 중심 투여 등을 꼽을 수 있습니다.
감염성 질환의 증가 추세는 향후 몇 년 동안 세팔로스포린 약물 시장의 성장을 촉진할 것으로 예상됩니다. 감염병은 세균, 바이러스, 곰팡이, 기생충 등 미생물에 의해 발생하여 개인 간 전염되는 질병을 말합니다. 감염증의 증가는 부분적으로 항균제 내성 증가에 기인하며, 이로 인해 기존에 치료할 수 있었던 감염증의 치료가 어려워져 더 광범위하고 지속적인 질병이 발생하고 있습니다. 세팔로스포린 약물은 광범위한 항균 활성을 가지고 다양한 세균 병원체를 효과적으로 표적화하여 이러한 감염성 질환의 치료에 기여합니다. 치료 기간 단축, 빠른 증상 완화, 환자 예후 개선을 가져옵니다. 예를 들어, 2024년 12월 스위스에 본부를 둔 국제보건기구인 세계보건기구(WHO)는 2023년 전 세계적으로 약 2억 6,300만 건의 말라리아가 발생하고 59만 7,000명의 말라리아 사망자가 발생했다고 보고했습니다. 이는 2022년에 비해 약 1,100만 건이 증가한 것으로 사망자 수는 거의 비슷한 수준이지만, 사망자의 약 95%가 WHO 아프리카 지역에서 발생했습니다. 그 결과, 감염성 질환의 확산이 세팔로스포린계 약품 시장의 확대를 촉진하고 있습니다.
세팔로스포린 약물 시장의 주요 기업들은 항균제 내성 대책 및 전 세계적으로 증가하는 약제 내성 감염에 대응하기 위해 그람음성균 감염 치료제 등 혁신적인 솔루션 개발에 주력하고 있습니다. 그람음성균 감염 치료에는 특수한 세포벽 구조로 인해 많은 기존 항생제에 내성을 보이는 그람음성균을 표적으로 하는 항생제가 사용됩니다. 예를 들어, 2024년 5월 일본 제약회사 시오노기제약은 다른 약제에 내성을 가진 균주를 포함한 중증 그람음성균 감염에 대한 새로운 항생제 '페트로자(세피데로콜)를 출시했습니다. 이 독특한 '트로이 목마' 메커니즘을 통해 여러 내성 장벽을 우회할 수 있어 치료 옵션이 제한적인 환자들에게 중요한 치료 옵션을 제공합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 공급망 분석
제4장 세계 시장 동향과 전략
제5장 최종 이용 산업 시장 분석
제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의가 공급망에 미치는 영향, 코로나가 시장에 미치는 영향을 포함한 거시경제 시나리오
제7장 세계의 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석
제8장 시장에서 세계의 총 잠재 시장 규모(TAM)
제9장 시장 세분화
제10장 지역별, 국가별 분석
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 인도네시아 시장
제17장 한국 시장
제18장 대만 시장
제19장 동남아시아 시장
제20장 서유럽 시장
제21장 영국 시장
제22장 독일 시장
제23장 프랑스 시장
제24장 이탈리아 시장
제25장 스페인 시장
제26장 동유럽 시장
제27장 러시아 시장
제28장 북미 시장
제29장 미국 시장
제30장 캐나다 시장
제31장 남미 시장
제32장 브라질 시장
제33장 중동 시장
제34장 아프리카 시장
제35장 시장 규제 상황과 투자 환경
제36장 경쟁 구도와 기업 개요
제37장 기타 주요 기업과 혁신적 기업
제38장 세계의 시장 경쟁 벤치마킹과 대시보드
제39장 주요 인수합병
제40장 시장 잠재력이 높은 국가, 부문, 전략
제41장 부록
KSM
영문 목차
영문목차
Cephalosporin drugs are a class of beta (B)-lactam antibiotics used to treat bacterial infections by inhibiting bacterial cell wall synthesis, leading to cell death. They are broad-spectrum antibiotics and are classified into generations based on their antimicrobial activity. Cephalosporins are commonly used to manage infections such as respiratory tract infections, skin infections, urinary tract infections, and meningitis.
The generations of cephalosporin drugs include first, second, third, fourth, and fifth generations. First-generation cephalosporins are mainly effective against gram-positive bacteria, such as streptococcus and staphylococcus species, with limited activity against gram-negative bacteria. They can be administered orally, parenterally, or topically. Their applications include treating skin infections, respiratory tract infections, urinary tract infections, sexually transmitted infections, ear infections, and other conditions. These drugs are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.
Tariffs have affected the cephalosporin drugs market by increasing the cost of imported active pharmaceutical ingredients, fermentation intermediates, and formulation inputs used in antibiotic manufacturing. These impacts are most pronounced in third- and fourth-generation cephalosporins, particularly in North America and Europe where API sourcing is globally diversified. Asia-Pacific producers have faced supply chain disruptions and margin pressure. However, tariffs have encouraged domestic API production and localized antibiotic manufacturing, supporting long-term supply security.
The cephalosporin drugs market research report is one of a series of new reports from The Business Research Company that provides cephalosporin drugs market statistics, including cephalosporin drugs industry global market size, regional shares, competitors with a cephalosporin drugs market share, detailed cephalosporin drugs market segments, market trends and opportunities, and any further data you may need to thrive in the cephalosporin drugs industry. This cephalosporin drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The cephalosporin drugs market size has grown steadily in recent years. It will grow from $17.17 billion in 2025 to $17.88 billion in 2026 at a compound annual growth rate (CAGR) of 4.1%. The growth in the historic period can be attributed to high burden of bacterial infections, proven clinical efficacy of cephalosporins, widespread physician familiarity, availability of multiple drug generations, expansion of hospital-based antibiotic use.
The cephalosporin drugs market size is expected to see steady growth in the next few years. It will grow to $21.02 billion in 2030 at a compound annual growth rate (CAGR) of 4.1%. The growth in the forecast period can be attributed to rising antimicrobial resistance concerns, demand for advanced generation antibiotics, expansion of hospital infrastructure, increasing surgical procedures, sustained demand in emerging healthcare markets. Major trends in the forecast period include continued demand for broad-spectrum antibiotics, widespread use across multiple infection types, increasing use of higher-generation cephalosporins, strong presence of generic drug formulations, hospital-centric administration of injectable cephalosporins.
The increasing prevalence of infectious diseases is expected to drive the growth of the cephalosporin drugs market in the coming years. Infectious diseases are illnesses caused by microorganisms such as bacteria, viruses, fungi, or parasites that can be transmitted between individuals. The rise in infectious diseases is partly due to increasing antimicrobial resistance, which makes previously treatable infections harder to cure, resulting in more widespread and persistent diseases. Cephalosporin drugs help treat these infections by offering broad-spectrum antibacterial activity, effectively targeting a variety of bacterial pathogens. They reduce treatment duration, provide rapid relief, and improve patient outcomes. For example, in December 2024, the World Health Organization, a Switzerland-based health organization, reported an estimated 263 million malaria cases and 597,000 malaria deaths worldwide in 2023. This represents roughly 11 million more cases than in 2022, with nearly the same number of deaths, and about 95% of fatalities occurring in the WHO African Region. Consequently, the growing prevalence of infectious diseases is fueling the expansion of the cephalosporin drugs market.
Leading companies in the cephalosporin drugs market are focusing on developing innovative solutions, such as treatments for gram-negative bacterial infections, to combat antimicrobial resistance and address the growing prevalence of drug-resistant infections worldwide. Treatments for gram-negative bacterial infections involve targeted antibiotics designed to eliminate gram-negative bacteria, which possess a unique cell wall structure that makes them more resistant to many conventional antibiotics. For example, in May 2024, Shionogi & Co. Ltd., a Japan-based pharmaceutical company, launched FETROJA (Cefiderocol), a novel antibiotic for serious gram-negative bacterial infections, including strains resistant to other drugs. Its unique "Trojan horse" mechanism enables it to bypass multiple resistance barriers, providing a critical treatment option for patients with limited alternatives.
In January 2024, Venatorx Pharmaceuticals Inc., a US-based pharmaceutical company, partnered with Menarini Group to acquire exclusive rights to commercialize cefepime-taniborbactam in 96 countries. This partnership aims to expand global access to the advanced antibiotic, targeting multidrug-resistant bacterial infections. Menarini Group, based in Italy, is a pharmaceutical company specializing in the development and production of cephalosporin drugs.
Major companies operating in the cephalosporin drugs market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., AstraZeneca plc, Abbott Laboratories, Novartis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Baxter International, Macleods Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd., Lupin Limited, Zydus Lifesciences Limited, Alkem Laboratories Ltd., Mankind Pharma Limited, Aristo Pharmaceuticals Ltd, Hetero Drugs Ltd, Covalent Laboratories Private Limited.
North America was the largest region in the cephalosporin drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cephalosporin drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the cephalosporin drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The cephalosporin drugs market consists of sales of keflex, rocephin, and maxipime. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Cephalosporin Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses cephalosporin drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for cephalosporin drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cephalosporin drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
Markets Covered:1) By Generation: First Generation; Second Generation; Third Generation; Fourth Generation; Fifth Generation
2) By Route of Administration: Oral; Parenteral; Topical
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
4.2.1 Continued Demand For Broad-Spectrum Antibiotics
4.2.2 Widespread Use Across Multiple Infection Types
4.2.3 Increasing Use Of Higher-Generation Cephalosporins
4.2.4 Strong Presence Of Generic Drug Formulations
4.2.5 Hospital-Centric Administration Of Injectable Cephalosporins
5. Cephalosporin Drugs Market Analysis Of End Use Industries
5.1 Hospitals
5.2 Retail Pharmacies
5.3 Online Pharmacies
5.4 Clinics
5.5 Diagnostic Centers
6. Cephalosporin Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Cephalosporin Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
7.1. Global Cephalosporin Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Cephalosporin Drugs Market Size, Comparisons And Growth Rate Analysis
7.3. Global Cephalosporin Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Cephalosporin Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Cephalosporin Drugs Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9. Cephalosporin Drugs Market Segmentation
9.1. Global Cephalosporin Drugs Market, Segmentation By Generation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
First Generation, Second Generation, Third Generation, Fourth Generation, Fifth Generation
9.2. Global Cephalosporin Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Oral, Parenteral, Topical
9.3. Global Cephalosporin Drugs Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Cephalosporin Drugs Market, Segmentation By Generation, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Cephalosporin Drugs Market
12.1. China Cephalosporin Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Cephalosporin Drugs Market, Segmentation By Generation, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Cephalosporin Drugs Market
13.1. India Cephalosporin Drugs Market, Segmentation By Generation, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Cephalosporin Drugs Market
14.1. Japan Cephalosporin Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Cephalosporin Drugs Market, Segmentation By Generation, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Cephalosporin Drugs Market
15.1. Australia Cephalosporin Drugs Market, Segmentation By Generation, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. Indonesia Cephalosporin Drugs Market
16.1. Indonesia Cephalosporin Drugs Market, Segmentation By Generation, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. South Korea Cephalosporin Drugs Market
17.1. South Korea Cephalosporin Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Cephalosporin Drugs Market, Segmentation By Generation, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
18. Taiwan Cephalosporin Drugs Market
18.1. Taiwan Cephalosporin Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Cephalosporin Drugs Market, Segmentation By Generation, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. South East Asia Cephalosporin Drugs Market
19.1. South East Asia Cephalosporin Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Cephalosporin Drugs Market, Segmentation By Generation, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. Western Europe Cephalosporin Drugs Market
20.1. Western Europe Cephalosporin Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Cephalosporin Drugs Market, Segmentation By Generation, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. UK Cephalosporin Drugs Market
21.1. UK Cephalosporin Drugs Market, Segmentation By Generation, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22. Germany Cephalosporin Drugs Market
22.1. Germany Cephalosporin Drugs Market, Segmentation By Generation, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. France Cephalosporin Drugs Market
23.1. France Cephalosporin Drugs Market, Segmentation By Generation, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
24. Italy Cephalosporin Drugs Market
24.1. Italy Cephalosporin Drugs Market, Segmentation By Generation, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25. Spain Cephalosporin Drugs Market
25.1. Spain Cephalosporin Drugs Market, Segmentation By Generation, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Eastern Europe Cephalosporin Drugs Market
26.1. Eastern Europe Cephalosporin Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Cephalosporin Drugs Market, Segmentation By Generation, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Russia Cephalosporin Drugs Market
27.1. Russia Cephalosporin Drugs Market, Segmentation By Generation, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. North America Cephalosporin Drugs Market
28.1. North America Cephalosporin Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Cephalosporin Drugs Market, Segmentation By Generation, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
29. USA Cephalosporin Drugs Market
29.1. USA Cephalosporin Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Cephalosporin Drugs Market, Segmentation By Generation, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
30. Canada Cephalosporin Drugs Market
30.1. Canada Cephalosporin Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Cephalosporin Drugs Market, Segmentation By Generation, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
31. South America Cephalosporin Drugs Market
31.1. South America Cephalosporin Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Cephalosporin Drugs Market, Segmentation By Generation, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
32. Brazil Cephalosporin Drugs Market
32.1. Brazil Cephalosporin Drugs Market, Segmentation By Generation, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
33. Middle East Cephalosporin Drugs Market
33.1. Middle East Cephalosporin Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Cephalosporin Drugs Market, Segmentation By Generation, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
34. Africa Cephalosporin Drugs Market
34.1. Africa Cephalosporin Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Cephalosporin Drugs Market, Segmentation By Generation, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
35. Cephalosporin Drugs Market Regulatory and Investment Landscape
36. Cephalosporin Drugs Market Competitive Landscape And Company Profiles
36.1. Cephalosporin Drugs Market Competitive Landscape And Market Share 2024
36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. Cephalosporin Drugs Market - Company Scoring Matrix
36.2.1. Market Revenues
36.2.2. Product Innovation Score
36.2.3. Brand Recognition
36.3. Cephalosporin Drugs Market Company Profiles
36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
36.3.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
36.3.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
36.3.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
36.3.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
37. Cephalosporin Drugs Market Other Major And Innovative Companies
